Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1801 1
1805 1
1928 1
1937 2
1939 1
1941 1
1945 3
1946 14
1947 12
1948 16
1949 11
1950 21
1951 11
1952 11
1953 21
1954 27
1955 51
1956 20
1957 23
1958 30
1959 15
1960 17
1961 18
1962 27
1963 34
1964 29
1965 17
1966 38
1967 33
1968 27
1969 30
1970 28
1971 35
1972 45
1973 25
1974 38
1975 30
1976 30
1977 36
1978 43
1979 42
1980 52
1981 31
1982 35
1983 34
1984 33
1985 39
1986 43
1987 30
1988 44
1989 54
1990 53
1991 38
1992 43
1993 43
1994 51
1995 45
1996 48
1997 42
1998 53
1999 41
2000 53
2001 65
2002 58
2003 55
2004 80
2005 74
2006 89
2007 81
2008 105
2009 93
2010 120
2011 137
2012 134
2013 145
2014 150
2015 184
2016 202
2017 160
2018 179
2019 173
2020 191
2021 220
2022 225
2023 197
2024 219
2025 183
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,966 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
Nowak RJ, Benatar M, Ciafaloni E, Howard JF Jr, Leite MI, Utsugisawa K, Vissing J, Rojavin M, Li Q, Tang F, Wu Y, Rampal N, Cheng S; MINT Investigators. Nowak RJ, et al. Among authors: howard jf jr. N Engl J Med. 2025 Jun 19;392(23):2309-2320. doi: 10.1056/NEJMoa2501561. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202593 Clinical Trial.
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Howard JF Jr, et al. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. Lancet Neurol. 2023. PMID: 37059508 Clinical Trial.
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
Granit V, Benatar M, Kurtoglu M, Miljković MD, Chahin N, Sahagian G, Feinberg MH, Slansky A, Vu T, Jewell CM, Singer MS, Kalayoglu MV, Howard JF Jr, Mozaffar T; MG-001 Study Team. Granit V, et al. Among authors: howard jf jr. Lancet Neurol. 2023 Jul;22(7):578-590. doi: 10.1016/S1474-4422(23)00194-1. Lancet Neurol. 2023. PMID: 37353278 Free PMC article. Clinical Trial.
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF Jr; CHAMPION MG Study Group. Meisel A, et al. Among authors: howard jf jr. J Neurol. 2023 Aug;270(8):3862-3875. doi: 10.1007/s00415-023-11699-x. Epub 2023 Apr 27. J Neurol. 2023. PMID: 37103755 Free PMC article. Clinical Trial.
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, Keeble T, Mielewczik M, Kaprielian R, Malik IS, Nijjer SS, Petraco R, Cook C, Ahmad Y, Howard J, Baker C, Sharp A, Gerber R, Talwar S, Assomull R, Mayet J, Wensel R, Collier D, Shun-Shin M, Thom SA, Davies JE, Francis DP; ORBITA investigators. Al-Lamee R, et al. Among authors: howard j. Lancet. 2018 Jan 6;391(10115):31-40. doi: 10.1016/S0140-6736(17)32714-9. Epub 2017 Nov 2. Lancet. 2018. PMID: 29103656 Free article. Clinical Trial.
Engineering CAR-T therapies for autoimmune disease and beyond.
English EP, Swingler RN, Patwa S, Tosun M, Howard JF Jr, Miljković MD, Jewell CM. English EP, et al. Among authors: howard jf jr. Sci Transl Med. 2024 Oct 30;16(771):eado2084. doi: 10.1126/scitranslmed.ado2084. Epub 2024 Oct 30. Sci Transl Med. 2024. PMID: 39475572 Review.
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
Howard JF Jr, Vu T, Li G, Korobko D, Smilowski M, Liu L, Gistelinck F, Steeland S, Noukens J, Van Hoorick B, Podhorna J, Borgions F, Li Y, Utsugisawa K, Wiendl H, De Bleecker JL, Mantegazza R; ADAPT-SC and ADAPT-SC+ Study Groups. Howard JF Jr, et al. Neurotherapeutics. 2024 Sep;21(5):e00378. doi: 10.1016/j.neurot.2024.e00378. Epub 2024 Sep 2. Neurotherapeutics. 2024. PMID: 39227284 Free PMC article. Clinical Trial.
A Digital Health Behavior Intervention to Prevent Childhood Obesity: The Greenlight Plus Randomized Clinical Trial.
Heerman WJ, Rothman RL, Sanders LM, Schildcrout JS, Flower KB, Delamater AM, Kay MC, Wood CT, Gross RS, Bian A, Adams LE, Sommer EC, Yin HS, Perrin EM; Greenlight Investigators; de la Barrera B, Bility M, Cruz Jimenez Smith M, Cruzatte EF, Guevara G, Howard JB, Lampkin J, Orr CJ, Pilotos McBride J, Quintana Forster L, Ramirez KS, Rodriguez J, Schilling S, Shepard WE, Soto A, Velazquez JJ, Wallace S. Heerman WJ, et al. Among authors: howard jb. JAMA. 2024 Dec 24;332(24):2068-2080. doi: 10.1001/jama.2024.22362. JAMA. 2024. PMID: 39489149 Free PMC article. Clinical Trial.
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, De Bleecker JL, Murai H, Meisel A, Beydoun SR, Pasnoor M, Guglietta A, Van Hoorick B, Steeland S, T'joen C, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT+ Study Group. Howard JF Jr, et al. Front Neurol. 2024 Jan 17;14:1284444. doi: 10.3389/fneur.2023.1284444. eCollection 2023. Front Neurol. 2024. PMID: 38318236 Free PMC article.
A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, Simader FA, Davies JR, O'Kane PD, Haworth P, Routledge H, Kotecha T, Gamma R, Clesham G, Williams R, Din J, Nijjer SS, Curzen N, Ruparelia N, Sinha M, Dungu JN, Ganesananthan S, Khamis R, Mughal L, Kinnaird T, Petraco R, Spratt JC, Sen S, Sehmi J, Collier DJ, Sohaib A, Keeble TR, Cole GD, Howard JP, Francis DP, Shun-Shin MJ, Al-Lamee RK; ORBITA-2 Investigators. Rajkumar CA, et al. Among authors: howard jp. N Engl J Med. 2023 Dec 21;389(25):2319-2330. doi: 10.1056/NEJMoa2310610. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 38015442 Free PMC article. Clinical Trial.
4,966 results